Healthcare · NIFTY 50

Sun Pharmaceutical Industries Limited

NSESUNPHARMA BSE524715 ISININE044A01036 SeriesEQ Listed on NSE · BSE

₹1,885.00 -17.30 (-0.91%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener

Price, daily close+10.06% in a year

Today

Open: ₹1,891.10
Prev close: ₹1,902.30
Day high: ₹1,896.80
Day low: ₹1,874.40
Volume: 24.64 L
Value traded: ₹464.58 Cr
Upper circuit: ₹1,948.70
Lower circuit: ₹1,835.30
52W high: ₹2,046.90
52W low: ₹1,583.70
1 month: +5.69%
6 months: -0.68%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹452,268 Cr

P/E (TTM)41.25

P/B5.07

Book value / share₹372.11

EPS (TTM)₹45.70

ROE12.3%

Dividend yield0.85%

Dividend (12m)₹16.00 / share

Net margin (TTM)17.8%

Operating margin21.5%

Debt / equity0.03

Current ratio2.94

EV / EBITDA27.11

Sales growth (YoY qtr)+11.88%

Profit growth (YoY qtr)-36.22%

Sales CAGR 3Y+10.03%

Profit CAGR 3Y+10.65%

Shares239.93 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

12,3812,524

Dec 23

11,9832,655

Mar 24

12,6532,836

Jun 24

13,2913,040

Sep 24

13,6752,903

Dec 24

12,9592,150

Mar 25

13,8512,279

Jun 25

14,4783,118

Sep 25

15,5213,369

Dec 25

14,6122,714

Mar 26

15,3002,895

Jun 26

16,1991,989

Sep 26

Revenue · QoQ (vs last quarter)

—-3.2%+5.6%+5.0%+2.9%-5.2%+6.9%+4.5%+7.2%-5.9%+4.7%+5.9%

Revenue · YoY (vs a year ago)

————+10%+8.1%+9.5%+8.9%+13%+13%+10%+12%

Net profit · QoQ (vs last quarter)

—+5.2%+6.8%+7.2%-4.5%-26%+6.0%+37%+8.0%-19%+6.7%-31%

Net profit · YoY (vs a year ago)

————+15%-19%-20%+2.6%+16%+26%+27%-36%

RevenueNet profitLine = trend

10.50

Dec 23

11.10

Mar 24

11.80

Jun 24

12.70

Sep 24

12.10

Dec 24

9.00

Mar 25

9.50

Jun 25

13.00

Sep 25

14.00

Dec 25

11.30

Mar 26

12.10

Jun 26

8.30

Sep 26

EPS (₹) · YoY (vs a year ago)

————+15%-19%-19%+2.4%+16%+26%+27%-36%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	12,381	11,983	12,653	13,291	13,675	12,959	13,851	14,478	15,521	14,612	15,300	16,199
Other income	250	606	533	354	466	613	464	470	579	459	724	517
Total income	12,631	12,589	13,185	13,645	14,141	13,572	14,316	14,948	16,099	15,070	16,024	16,716
Raw material	1,710	1,677	1,557	1,639	1,408	1,845	1,772	1,622	1,813	2,182	2,026	2,319
Purchases	796	983	997	875	1,239	1,037	1,048	1,088	922	753	1,020	1,143
Employee cost	2,363	2,299	2,455	2,478	2,552	2,489	2,802	2,765	2,892	2,960	3,227	3,274
Other expenses	3,804	4,268	3,915	4,181	4,374	4,117	3,933	4,204	4,735	4,896	4,692	5,084
Total expenses	9,561	9,672	9,762	10,048	10,349	9,956	10,325	10,781	11,383	11,519	11,721	12,288
Operating profit	3,407	2,934	3,608	3,939	3,693	3,354	3,484	4,527	4,459	3,954	4,214	3,475
OPM %	27.5%	24.5%	28.5%	29.6%	27.0%	25.9%	25.2%	31.3%	28.7%	27.1%	27.5%	21.5%
Finance cost	34.7	73.6	61.5	69.2	51.5	49.1	74.8	99.9	78.4	85.9	99.7	74.7
Depreciation	622	650	655	626	631	664	701	730	732	775	739	758
Exceptional items	-69.8	-102	—	—	-316	-362	-818	—	-489	—	-204	-1,269
Profit before tax	3,000	2,816	3,424	3,598	3,476	3,254	3,173	4,168	4,227	3,551	4,099	3,159
Tax	432	149	552	567	559	1,094	870	1,031	826	828	1,188	1,158
Net profit	2,561	2,659	2,861	3,037	2,913	2,154	2,293	3,125	3,381	2,710	2,901	1,995
Profit to shareholders	2,524	2,655	2,836	3,040	2,903	2,150	2,279	3,118	3,369	2,714	2,895	1,989
EPS (₹)	10.50	11.10	11.80	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10	8.30

Profit & loss

Results for each year

8 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

29,0665,0932,665

FY19

32,8386,7293,765

FY20

33,4984,1852,904

FY21

38,6545,8313,273

FY22

43,88611,4758,474

FY23

48,49712,5299,576

FY24

52,57814,59410,929

FY25

58,46216,42411,479

FY26

Revenue · YoY (vs a year ago)

—+13%+2.0%+15%+14%+11%+8.4%+11%

Net profit · YoY (vs a year ago)

—+41%-23%+13%+159%+13%+14%+5.0%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	29,066	32,838	33,498	38,654	43,886	48,497	52,578	58,462
Other income	1,025	636	836	922	635	1,354	1,965	1,972
Total expenses	25,067	28,203	27,228	30,528	34,940	38,269	40,114	44,007
Employee cost	5,967	6,362	6,862	7,301	8,296	9,429	9,973	11,419
Operating profit	5,093	6,729	4,185	5,831	11,475	12,529	14,594	16,424
OPM %	17.5%	20.5%	12.5%	15.1%	26.1%	25.8%	27.8%	28.1%
Finance cost	555	303	141	127	172	238	231	339
Depreciation	1,753	2,053	2,080	2,144	2,529	2,557	2,575	2,938
Profit before tax	3,810	5,010	2,799	4,481	9,408	11,088	13,752	15,119
Tax	601	823	515	1,076	848	1,439	2,772	3,554
Tax rate %	15.8%	16.4%	18.4%	24.0%	9.0%	13.0%	20.2%	23.5%
Net profit	3,208	4,172	2,272	3,389	8,513	9,610	10,965	11,509
Profit to shareholders	2,665	3,765	2,904	3,273	8,474	9,576	10,929	11,479
Net margin %	9.2%	11.5%	8.7%	8.5%	19.3%	19.7%	20.8%	19.6%
EPS (₹)	11.11	15.69	12.10	13.60	35.30	39.90	45.60	47.80

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

55,9956,1984,624

Mar 23

63,6672,8469,286

Mar 24

72,2181,87010,269

Mar 25

83,5704,0829,771

Mar 26

89,2802,69318,401

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+14%+13%+16%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	55,995	63,667	72,218	83,570	89,280
Long-term borrowings	0.0	1.3	2.5	31.3	66.7
Short-term borrowings	6,198	2,844	1,867	4,050	2,627
Total borrowings	6,198	2,846	1,870	4,082	2,693
Current liabilities	19,906	16,984	18,194	22,622	23,592
Fixed assets (PPE)	10,390	10,192	10,036	11,114	11,141
Inventories	10,513	9,868	10,243	11,493	12,592
Trade receivables	11,439	11,249	13,046	15,510	17,805
Cash & equivalents	4,624	9,286	10,269	9,771	18,401
Current assets	39,862	43,433	52,594	63,860	69,267
Total assets	80,744	85,463	92,101	108,785	114,838
Debt / equity	0.11	0.04	0.03	0.05	0.03

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

8,985-5,725-5,193

FY22

4,959-7,9442,376

FY23

12,135-690-6,710

FY24

14,072-5,306-7,906

FY25

12,419-11,344-2,513

FY26

Operations · YoY (vs a year ago)

—-45%+145%+16%-12%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	8,985	4,959	12,135	14,072	12,419
Cash from investing	-5,725	-7,944	-690	-5,306	-11,344
Cash from financing	-5,193	2,376	-6,710	-7,906	-2,513
Spent on fixed assets	-1,495	-2,086	-2,202	-2,129	-3,609
Free cash flow	7,490	2,874	9,933	11,944	8,810
Net cash flow	-1,934	-608	4,735	860	-1,437

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

54.5%Dec 23

54.5%Mar 24

54.5%Jun 24

54.5%Sep 24

54.5%Dec 24

54.5%Mar 25

54.5%Jun 25

54.5%Sep 25

54.5%Dec 25

54.5%Mar 26

54.5%Jun 26

52.7%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

52.7%promoter

Promoter & group: 52.68%
Public (FIIs, mutual funds, retail…): 47.32%
Promoter change, last quarter: -1.80 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Dividend - Rs 5 Per ShareEx 07-Jul-2026
Interim Dividend - Rs 11 Per ShareEx 05-Feb-2026
Dividend - Rs 5.50 Per ShareEx 07-Jul-2025
Interim Dividend - Rs 10.50 Per ShareEx 06-Feb-2025
Dividend - Rs 5 Per ShareEx 12-Jul-2024
Interim Dividend - Rs 8.50 Per ShareEx 09-Feb-2024
Dividend - Rs 4 Per ShareEx 28-Jul-2023
Interim Dividend - Rs 7.50 Per ShareEx 08-Feb-2023

Board meetings

Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to inter-alia consider and approve the …30-Oct-2026
Board Meeting Intimation for consideration and approval the Unaudited Financial Results for the quarter and half year ended 30 September 202630-Oct-2026
Fund raising.12-Oct-2026
Board meeting intimation for consideration and approval of the issuance of listed, rated, unsecured, redeemable, non-convertible debentures12-Oct-2026
SUN PHARMACEUTICAL INDUSTRIES LIMITED has informed the Exchange about Board Meeting to be held on 31-Jul-2026 to inter-alia consider and approve the …31-Jul-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates5 Nov
Analysts/Institutional Investor Meet/Con. Call Updates4 Nov
News Verification4 Nov
Rumour Verification - Regulation 30(11)2 Nov
General Updates31 Oct
Copy of Newspaper Publication31 Oct
Analysts/Institutional Investor Meet/Con. Call Updates30 Oct

Latest news

Sun Pharma down 2%, stock hits over 5-month lowBusiness Standard · 14 Oct, 12:30 pm Sun Pharma, Coforge: Indian businesses go shopping abroad as growth slows at homeBBC · 24 May, 12:30 pm Sun Pharmaceutical Industries Ltd Stock Price: Sun Pharma.Inds. Share Price TodayIndia Infoline · 8 Jun, 6:43 pm Sun Pharmaceutical Industries shares fall 2.02%; stock among top losers on Nifty 50TradingView · 17 Aug, 12:30 pm Sun Pharma completes $11.75bn financing syndication for Organon acquisitionGenerics and Biosimilars Initiative · 20 Aug, 4:08 pm Sun Pharmaceutical Industries (NSEI:SUNPHARMA) Stock Forecast & Analyst PredictionsSimply Wall St · 3 Nov, 1:30 pm SPARC Share Price: Sun Pharma Advanced Research SharesUnivest · 9 Nov, 5:15 pm Sun Pharmaceutical Industries Ltd. Share Price Live TodayCNBC TV18 · 3 Jan, 12:24 pm

About

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Sun Pharmaceutical Industries Limited
NSE symbol: SUNPHARMA
BSE scrip code: 524715
ISIN: INE044A01036
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 8 Feb 1995
Face value: ₹1 per share
Market lot: 1 share
Shares issued: 239.93 crore
Index: NIFTY 50, NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Kirti Ganorkar
Chair: Dilip Shanghvi
Headquarters: Mumbai, Maharashtra, India
Registered address: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400 063, Maharashtra, India
Founded: 1983
Employees: 28,925
Financial year: April to March
Results basis: Consolidated
Website: sunpharma.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Sun Pharmaceutical Industries Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers